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BACKGROUND: We investigated the association between skin rash and plasma creatine kinase (CK) levels in oncology phase I trials.
METHODS: We analysed data from 295 patients treated at our institution within 25 phase I trials which included CK measurements in
the protocol. Trials involved drugs targeting EGFR/HER2, m-TOR, VEGFR, SRC/ABL, aurora kinase, BRAF/MEK, PARP, CDK, A5B1
integrin, as well as oncolytic viruses and vascular disrupting agents.
RESULTS: Creatine kinase measurements were available for 278 patients. The highest levels of plasma CK during the trial were seen
among patients with Grade (G) 2/3 rash (median 249U l 1) compared with G1 (median 81U l 1) and no rash (median 55U l 1)
(Po0.001). There was a significant reduction in CK after the rash resolved (mean 264.2 vs 100.1; P¼ 0.012) in 25 patients, where
serial CK values were available. In vitro exposure of human keratinocytes to EGFR, MEK and a PI3Kinase/m-TOR inhibitor led to the
increased expression of CK-brain and not CK-muscle or mitochondrial-CK.
CONCLUSION: Plasma CK elevation is associated with development of skin rash caused by novel anticancer agents. This should be studied
further to characterise different isoforms as this will change the way we report adverse events in oncology phase I clinical trials.
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The patterns of toxicities caused by anticancer agents have
changed with the advent of the development of targeted agents,
and myelotoxicity is no longer the predominant limiting toxicity.
Skin rash is a frequent side-effect of targeted anticancer drugs
including drugs inhibiting the EGFR–RAS–RAF–MEK and PI3
kinase–AKT–m-TOR pathways (Figure 1) (Moore et al, 2007;
O’Donnell et al, 2008; Banerji et al, 2010; Flaherty et al, 2010; Yap
et al, 2010; Moreno Garcia et al, 2011).
Creatine (Cr) and creatine kinase (CK) have an important role in
human soft tissue. In the cell, CK catalyses the reversible
phosphorylation between ATP and Cr to produce phosphocreatine
(PCr) and ADP, acting as a cytosolic energy buffer. Three
predominant isoforms of CK exist with different subcellular
locations: two cytosolic isoforms (CK-muscle (CK-M) and CK-
brain (CK-B)) and one mitochondrial isoform (mitochondrial-
CK (mt-CK)) (Wallimann et al, 2011). Cytosolic isotypes form
homo- or hetero-dimers with tissue specificity: CK-MM (muscle),
CK-MB (heart) and CK-BB (brain and skin) (Schlattner et al,
2002). During wound healing, keratinocytes overexpress CK-BB to
cope with the increased metabolism caused by nucleotide
biosynthesis (Schlattner et al, 2002). We hypothesised that skin
toxicity caused by novel anticancer agents was associated with
keratinocyte stress, thus leading to increased levels of CK in the
skin and possibly circulating CK levels in the plasma. We thus
aimed to study the association, if any, of plasma CK in patients
who developed skin rash in phase I trials.
METHODS
Trial and patient inclusion
This was a retrospective study including 295 consecutive patients
treated within phase I clinical trials at the Drug Development Unit,
Royal Marsden Hospital, Sutton, UK. We reviewed 104 trial
protocols and found 25 that mandated regular plasma CK
measurements. All patients consented to individual phase I clinical
trials that were approved by the institutional research ethics
committee, and this project was reviewed by the Royal Marsden
Hospital Audit Committee.
Data collection
Compliance to CK measurement during the trial was assessed.
To assess the dynamics of CK, we included several data points:
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baseline CK, first elevation (level and day) and highest level (and
day of highest level). A complete list of concomitant medications
(such as use of statins) was not available. The baseline plasma CK
elevation was defined as levels above 140U l 1 by local laboratory
reference ranges. To avoid potential bias due to baseline elevation
or significant changes below the threshold of CK elevation, we also
calculated the ratio: higher CK-on trial/baseline CK and considered
‘increased CK’ if the ratio was X1.5. The 1.5-fold cutoff was
arbitrary. If rash occurred, we attempted to collect CK measure-
ments at time points when the rash resolved, if documented.
Representative photographs of skin rash caused by MEK and AKT
inhibitors were taken after informed consent from patients and
have been anonymised.
Please see Supplementary Data for tissue culture, chemical
reagents and western blotting.
Statistical analysis
To compare the difference between changes in plasma CK, and
because of the limited number of patients with skin rash, we
performed non-parametric tests. Mann–Whitney U and Kruskal–
Wallis one-way analysis of variance tests were used to compare CK
levels with rash when two or three categories were included,
respectively. The Wilcoxon test was used to analyse paired CK
values at diagnosis and resolution of rash. For categorical
variables, w2 and Fisher’s exact test were used as required. A
P-value of p0.05 was considered statistically significant and all
tests were two-tailed. SPSS v13.0.1 (IBM, Portsmouth, UK) was
used for all the analyses.
RESULTS
Data from 295 patients were considered in the analysis. CK
measurements were available for 278 patients (94%), indicating
compliance to protocol. For further analysis of the association of
CK and skin rash, only the 278 patients who had CK measurement
on file were used. Sixty-four patients (23%) developed a high CK
during the study, including 42 (15%) patients who had an 1.5
elevation compared with baseline during the study. In 25 patients
who developed rash, it was possible to find documented paired
CK at development and resolution of rash. Fifty patients (18%)
developed drug-induced skin rash during the trial (Figure 1).
There was an association between development of rash and CK
rise; 17% (39 out of 228) of patients who did not develop skin rash
had a CK rise during the trial compared with 35% (9 out of 26) of
patients who developed G1 and 67% (16 out of 24) of patients who
developed G2/3 rash (Po0.001). The levels of CK during the trial
were significantly elevated among patients with G2/3 rash (mean
406U l 1; median 249U l 1) compared with G1 (mean 127U l 1;
median 81U l 1; P¼ 0.01) and no rash (mean 92U l 1; median 55;
Po0.001; Figure 2. In addition, it was possible to find documented
CK when rash developed and when it resolved in 25 cases. There
was significant difference in the CK during rash and CK at
resolution (mean 264.2 vs 100.1; P¼ 0.012).
In vitro analysis
Adult human keratinocytes were exposed to increasing concentra-
tions of an EGFR (gefitinib), PI3K/m-TOR (PI-103) and MEK
inhibitor (PD0325901) at increasing doses for 24 h. The expression
of CK-B, CK-M and mt-CK was studied in the lysates. There was
an increase in the expression of CK-B (Figure 3). CK-M and
mt-CK were not detected in the lysates.
DISCUSSION
This is the first time that an association between skin rash and
elevated plasma CK in patients treated with different novel
anticancer agents has been reported. Further pointers that the
association is real are the fact that there was a temporal
relationship between the CK levels dropping when the rash
*Bars represent 95% confidence interval (CI)
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Figure 2 Serum creatine kinase levels and rash grade. Two hundred and
seventy-eight patients with available CK measurements were included in
the analysis. The highest CK level on study was selected for analysis.
Figure 1 Types of skin rash caused by molecularly targeted agents. Skin
rash often causes dose-limiting toxicities in phase I trials of molecularly
targeted agents. (A) Acneiform skin rash typical of EGFR or MEK inhibitors.
(B) Maculopapular skin rash typical of PI3K, AKT or m-TOR inhibitors.
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resolved in a subset of patients where this data was available and
the fact that the relationship between skin rash and CK seem to
spread across a wide range of tumours and anticancer agents
(Supplementary Table 1). However, this study has the limitations
of a retrospective analysis and only total CK and not its specific
isoforms were measured. CK is known to be elevated in patients
treated with a range of drugs such as statins (Stolcpart et al, 2010)
and anticancer agents, trabectedin (Stoyianni et al, 2011) and
imatinib (Gordon et al, 2010). In most instances these elevations
are thought to be due to inflammation in muscles and relate to CK-
MM. CK-BB subtype is usually undetectable in serum but can be
responsible for 1–18% of the total CK activity (Skogseid et al, 1992;
Kovesdi et al, 2010). It has also been found to be overexpressed in
different tumour cells, such as breast (Zarghami et al, 1996) and
lung (Niklinski et al, 1991) cancers. CK elevation has also been
reported in patients with toxic epidermal necrosis. However, it was
found that CK elevation of CK-BB fraction represented only 3% of
the serum total CK whereas 94% was CK-MM (Caux et al, 1994).
The present analysis includes total plasma CK measurement and
does not differentiate between isotypes.
We conducted preclinical experiments to explore this further.
We detected a rise in expression of CK-B in keratinocytes after
in vitro exposure to EGFR, PI3K/m-TOR and MEK inhibitors. This
was consistent with previous reports that there was an increased
expression of CK-BB in keratinocytes, when they were under stress
(Schlattner et al, 2002), or in exudates within blisters (Paavonen
et al, 1988; Kiistala et al, 1989). It is therefore possible that the rise
in plasma CK associated with skin toxicity is due to a rise in CK-
BB, and this has not been documented before. Future studies
should analyse different circulating isoforms of CK to find the
source of the rise of plasma CK associated with skin rash.
These findings have several clinical implications. First, at
present, a raised CK would be reported as a musculoskeletal
adverse or serious adverse event in phase I trials. However, it is
possible that these are manifestations of skin toxicity. Second,
these findings may give an insight into the treatment of skin
rash. It has previously been shown that repair mechanisms in
keratinocytes require ATP. The free energy of ATP is stored and
transported in the form of PCr, where CK activity can replenish
cellular ATP in situ and exogenous Cre protected against free
radical stress (Lenz et al, 2005). On the basis of the observations
that skin rash is associated with a raised CK and keratinocytes
show increased expression of CK (CK-B) after exposure to
different signal transduction agents, it could be hypothesised that
topical Cre supplementation (to increase the PCr cytosolic energy
buffer in keratinocytes) may be useful to prevent or treat rash
caused by novel anticancer agents. Indeed, topical Cre has been
investigated for the treatment of skin damage associated with UV
light (Lenz et al, 2005; Knott et al, 2008). In conclusion, this is the
first report of an association of skin rash and total circulating CK
in the setting of phase I trials of novel anticancer agents. This has
a number of clinical implications that include adverse event
reporting and the clinical management of rash. These findings
merit further prospective evaluation in clinical trials.
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